What is the clinical evidence from this study?

Study design: Cohort. Population: Breast cancer (n=96). Intervention: Breast cancer and its treatment. Primary outcome: Return to work at the end of treatment.

October 1, 2008Occupational MedicineOpen Access

By the end of treatment, 56% of breast cancer survivors who were employed at diagnosis had returned to work, with the presence of sequelae significantly associated with continuing sick leave.

View Full Paper

Ask AI

Bookmark

Population

96 consecutive patients with a primary diagnosis of breast cancer, aged between 18 and 65 years, who were…

Design

Cohort

Follow-up

mean time since diagnosis 32.5 months

Key result

By the end of treatment, 56% of breast cancer survivors who were employed at diagnosis had returned to work, with the presence of sequelae significantly associated with continuing sick leave.

Authors

RVR. Molina Villaverde JBJaime Feliú Batlle AYA. Villalba Yllán

Discussion

Member takes

Overview

Sequelae may prolong sick leave after breast cancer; leaves open whether targeted management improves employment outcomes.

Study Design

Type

Cohort (n=96)

Multicenter

Yes

Structured PICO

Population

96 breast cancer patients aged 18 to 65 years who were employed full-time at diagnosis, evaluated at a mean of 32.5 months post-diagnosis to assess return to work.

Outcome

Employment and work-related disability (ability to work after diagnosis and at the end of treatment)patient reported

Breast cancer survivors face challenges returning to work primarily due to disease and treatment sequelae rather than workplace discrimination.

Limitations

Regional sample from a metropolitan area may not be representative of other parts of the country.
Data on employment and social support were self-reported and might not fully reflect family and workplace characteristics.
Questions regarding discrimination were subject to patient interpretation.
Lack of a non-cancer comparison group makes it impossible to disentangle changes due to other factors from those due to cancer.
Regional sample from a metropolitan area may not be representative of the whole country
Data on employment and social support were self-reported
Questions regarding discrimination were subject to patient interpretation
Lack of a non-cancer comparison group

Cite This Study

Villaverde et al. (2008) conducted a cohort in Breast cancer (n=96). Breast cancer and its treatment was evaluated on Return to work at the end of treatment. By the end of treatment, 56% of breast cancer survivors who were employed at diagnosis had returned to work, with the presence of sequelae significantly associated with continuing sick leave.

synapsesocial.com/papers/6a97e7ce8818801a6fe17feb https://doi.org/10.1093/occmed/kqn092

View Full Paper

Ask AI

Bookmark

October 1, 2008Occupational MedicineOpen Access

By the end of treatment, 56% of breast cancer survivors who were employed at diagnosis had returned to work, with the presence of sequelae significantly associated with continuing sick leave.

View Full Paper

Ask AI

Bookmark

Population

96 consecutive patients with a primary diagnosis of breast cancer, aged between 18 and 65 years, who were…

Design

Cohort

Follow-up

mean time since diagnosis 32.5 months

Key result

By the end of treatment, 56% of breast cancer survivors who were employed at diagnosis had returned to work, with the presence of sequelae significantly associated with continuing sick leave.

Authors

RVR. Molina Villaverde JBJaime Feliú Batlle AYA. Villalba Yllán

Discussion

Member takes

Overview

Sequelae may prolong sick leave after breast cancer; leaves open whether targeted management improves employment outcomes.

Study Design

Type

Cohort (n=96)

Multicenter

Yes

Structured PICO

Population

96 breast cancer patients aged 18 to 65 years who were employed full-time at diagnosis, evaluated at a mean of 32.5 months post-diagnosis to assess return to work.

Outcome

Employment and work-related disability (ability to work after diagnosis and at the end of treatment)patient reported

Breast cancer survivors face challenges returning to work primarily due to disease and treatment sequelae rather than workplace discrimination.

Limitations

Regional sample from a metropolitan area may not be representative of other parts of the country.
Data on employment and social support were self-reported and might not fully reflect family and workplace characteristics.
Questions regarding discrimination were subject to patient interpretation.
Lack of a non-cancer comparison group makes it impossible to disentangle changes due to other factors from those due to cancer.
Regional sample from a metropolitan area may not be representative of the whole country
Data on employment and social support were self-reported
Questions regarding discrimination were subject to patient interpretation
Lack of a non-cancer comparison group

Cite This Study

synapsesocial.com/papers/6a97e7ce8818801a6fe17feb https://doi.org/10.1093/occmed/kqn092

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark